Eli Lilly Stock in Focus After Slashing Cost of Popular Drug

Core Viewpoint - Eli Lilly and Co is experiencing a decline in share price following the announcement of price cuts for its weight loss drug Zepbound, which may impact investor sentiment and market performance [1][2]. Group 1: Price Changes - The prices for Zepbound's single-dose vials have been reduced to $299 for the 2.5 mg vial and $399 for the 5 mg vial, down from previous prices of $349 and $499 respectively [1]. - The new pricing will be available through the company's direct-to-consumer platform, LillyDirect [1]. Group 2: Stock Performance - Eli Lilly's shares are down 0.8%, trading at $1,066.96, marking the third consecutive daily loss and a pullback from last week's record high of $1,112 [1][2]. - Despite the recent decline, the stock has shown a 34% year-over-year increase, indicating strong long-term performance [2]. Group 3: Options Activity - There has been an increase in call options activity, with a call/put volume ratio of 2.23, ranking higher than 93% of readings from the past year [2]. - The Schaeffer's put/call open interest ratio (SOIR) stands at 0.70, indicating that short-term traders are placing bullish bets [3]. - Eli Lilly's Schaeffer's Volatility Index (SVI) is at 31%, suggesting that near-term option traders are anticipating relatively low volatility [3].